DDInter393 DDInter1435
Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarithromycin may be bacteriostatic or bactericidal depending on the organism and drug concentration.
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Clarithromycin {u} (Compound) resembles {v} (Compound) Troleandomycin
Clarithromycin {u} (Compound) resembles {v} (Compound) Josamycin
Clarithromycin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Azithromycin
Clarithromycin {u} (Compound) binds {v} (Gene) ABCB1
Clarithromycin {u} (Compound) upregulates {v} (Gene) SLC25A14
Clarithromycin {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 3A4 Inhibitors
Clarithromycin {u} (Compound) downregulates {v} (Gene) TIMM9
Clarithromycin {u} (Compound) causes {v} (Side Effect) Gingival bleeding
Clarithromycin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Amoxicillin
Clarithromycin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cannabidiol
Clarithromycin (Compound) resembles Troleandomycin (Compound)
Clarithromycin (Compound) resembles Josamycin (Compound)
Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Azithromycin
Clarithromycin (Compound) binds ABCB1 (Gene)
Clarithromycin (Compound) upregulates SLC25A14 (Gene)
Clarithromycin (Compound) is included by Cytochrome P450 3A4 Inhibitors (Pharmacologic Class)
Clarithromycin (Compound) downregulates TIMM9 (Gene)
Clarithromycin (Compound) causes Gingival bleeding (Side Effect)
Clarithromycin may cause a minor interaction that can limit clinical effects when taken with Amoxicillin
Clarithromycin may cause a minor interaction that can limit clinical effects when taken with Cannabidiol